When should a beta‑blocker, an ACE inhibitor, and a mineralocorticoid receptor antagonist be initiated in a patient with heart failure or acute coronary syndrome?

When to Initiate Beta-Blocker, ACE Inhibitor, and Mineralocorticoid Receptor Antagonist

In patients with heart failure with reduced ejection fraction (HFrEF, LVEF ≤40%) or post-acute coronary syndrome, initiate an ACE inhibitor and beta-blocker as first-line therapy as soon as the patient is hemodynamically stable, followed by addition of an MRA for those with NYHA class II-IV symptoms or post-MI with diabetes/heart failure. 1, 2

Heart Failure with Reduced Ejection Fraction

First-Line Therapy: ACE Inhibitor + Beta-Blocker

Start both medications early in stable patients with HFrEF (LVEF ≤40%) 3, 2:

• ACE inhibitor: Initiate first in most cases, starting with low doses and titrating every 1-2 weeks 3

  • Target doses proven in trials (e.g., enalapril 10-20 mg twice daily)
  • Check renal function and potassium 1-2 weeks after initiation and dose changes 3

• Beta-blocker: Add after ACE inhibitor initiation (though can be started simultaneously in stable patients) 4

  • Only use evidence-based agents: bisoprolol (1.25 mg → 10 mg daily), carvedilol (3.125 mg → 25-50 mg twice daily), or metoprolol CR/XL (12.5-25 mg → 200 mg daily) 4
  • Double dose at minimum 2-week intervals 4
  • Some beta-blocker is better than no beta-blocker - aim for target doses but accept maximum tolerated dose 4

Key timing considerations:

• Start in stable outpatients with NYHA class II-IV symptoms 4
• For hospitalized patients: Can continue existing beta-blockers if hemodynamically stable; initiate or restart within 24 hours if no contraindications (no acute heart failure Killip class II-IV, no cardiogenic shock, no severe bradycardia/heart block) 2, 1
• Do NOT initiate during acute decompensation with signs of congestion (raised JVP, marked edema) or in unstable patients requiring inotropes 4

Second-Line Therapy: Mineralocorticoid Receptor Antagonist

Add an MRA for patients already on ACE inhibitor + beta-blocker with 5, 3, 6:

• NYHA class III-IV symptoms (advanced heart failure) 5
• NYHA class II-IV with recent hospitalization, elevated natriuretic peptides, or diabetes 7
• Post-MI with LVEF ≤40% and diabetes or heart failure symptoms 8, 1

Dosing and monitoring 6:

• Spironolactone: Start 12.5 mg daily → target 50 mg daily
• Eplerenone: Start 25 mg daily → target 50 mg daily
• Critical safety checks: Potassium must be <5.0 mmol/L and creatinine <221 μmol/L (<2.5 mg/dL) before starting 3
• Check potassium and creatinine after 5-7 days, then regularly 5
• Avoid potassium supplements and NSAIDs 5, 3

Acute Coronary Syndrome

Immediate Post-ACS Management

For all ACS patients 1:

1. Beta-blocker: Initiate within 24 hours if no contraindications (no acute HF, no cardiogenic shock, no severe bradycardia/heart block, no active bronchospasm) 1

   • Continue indefinitely in all post-MI patients 8
   • Reassess at 24 hours if initially contraindicated 1

2. ACE inhibitor: Start early, especially in high-risk patients 1:

   • Mandatory for LVEF ≤40%, hypertension, diabetes, or anterior STEMI 8, 1
   • Reasonable for all other ACS patients 1
   • Continue indefinitely 8

3. MRA: Add for post-MI patients with 1:

   • LVEF ≤40% AND (diabetes OR heart failure symptoms)
   • Must exclude significant renal dysfunction or hyperkalemia (K+ >5.0 mmol/L) 1
   • Start after stabilization on ACE inhibitor and beta-blocker

Sequencing Algorithm

The traditional approach (ACE inhibitor first, then beta-blocker) remains standard, though recent evidence suggests either sequence is acceptable in stable patients 9. The 2025 ACC/AHA guidelines emphasize early initiation of both in appropriate candidates 1.

Common Pitfalls and Monitoring

Avoid these errors:

• Never stop beta-blockers abruptly - risk of rebound ischemia and arrhythmias 4
• Don't combine potassium-sparing diuretics with MRA during initiation 5
• Don't use NSAIDs - interfere with all three drug classes 5, 3
• Don't assume all beta-blockers are equivalent - only bisoprolol, carvedilol, and metoprolol CR/XL have mortality benefit in HF 4

Monitoring schedule 3:

• Blood pressure, heart rate, symptoms at each visit
• Renal function and electrolytes: 1-2 weeks after initiation, 1-2 weeks after each dose change, then every 4-6 months
• Watch for hyperkalemia (most common MRA adverse effect - occurs in ~40% of patients) 10, 11

Dose adjustment triggers 4:

• Worsening congestion: Increase diuretics first, not reduce beta-blocker
• Symptomatic hypotension: Reduce vasodilators/diuretics before stopping proven therapies
• Heart rate <50 bpm with symptoms: Consider reducing beta-blocker dose
• Asymptomatic low blood pressure: Usually requires no change